Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Grows By 301.8%

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 195,700 shares, a growth of 301.8% from the October 15th total of 48,700 shares. Based on an average daily volume of 1,660,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.4% of the company’s shares are sold short.

Windtree Therapeutics Price Performance

WINT remained flat at $0.60 during trading on Tuesday. 41,471 shares of the company’s stock were exchanged, compared to its average volume of 768,918. The company has a 50 day simple moving average of $1.75 and a 200-day simple moving average of $4.23. Windtree Therapeutics has a twelve month low of $0.53 and a twelve month high of $22.36. The stock has a market capitalization of $354,000.00, a PE ratio of -0.02 and a beta of 0.64.

Windtree Therapeutics (NASDAQ:WINT) last announced its quarterly earnings data on Monday, August 19th. The company reported ($20.91) EPS for the quarter, missing analysts’ consensus estimates of ($8.11) by ($12.80). Equities research analysts anticipate that Windtree Therapeutics will post -2.38 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.